vTv Therapeutics Inc.

The company is a clinical-stage biopharmaceutical firm that discovers and develops oral therapies for metabolic and inflammatory conditions. Its primary drug candidate is cadisegliatin, an oral liver-selective glucokinase activator in late-stage development as an add-on treatment to insulin for individuals with type 1 and type 2 diabetes. Its broader research pipeline features oral small molecules including a GLP-1 receptor agonist for diabetes management, a preclinical RAGE antagonist, Nrf2 pathway activators for inflammation, and a globally licensed PDE4 inhibitor. The company targets patients suffering from chronic metabolic and autoimmune disorders, while collaborating with commercial partners and research institutions.

The company conducts clinical development programs and maintains commercial partnerships across the United States, the Middle East, Africa, Central Asia, and the Pacific Rim. Its clinical operations encompass multiple studies, including a Phase 3 study evaluating 150 patients and a 300-patient regional study. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of vTv Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025 we had twenty-six employees and none of our employees are represented by a labor union, and we consider our employee relations to be good.”